Last reviewed · How we verify
Progesterone Vaginal Product
Progesterone binds to progesterone receptors in the reproductive tract to support luteal phase function and maintain pregnancy.
Progesterone binds to progesterone receptors in the reproductive tract to support luteal phase function and maintain pregnancy. Used for Luteal phase support in assisted reproductive technology (ART), Pregnancy maintenance in women with progesterone deficiency.
At a glance
| Generic name | Progesterone Vaginal Product |
|---|---|
| Also known as | Utrogestan |
| Sponsor | UMC Utrecht |
| Drug class | Progestin |
| Target | Progesterone receptor (PR) |
| Modality | Small molecule |
| Therapeutic area | Reproductive Health / Obstetrics |
| Phase | FDA-approved |
Mechanism of action
Progesterone is a naturally occurring steroid hormone that acts as a ligand for progesterone receptors (PR-A and PR-B) in endometrial and vaginal tissues. When administered vaginally, it provides local and systemic progesterone supplementation to support endometrial secretion, reduce uterine contractility, and maintain pregnancy in the luteal phase. This is particularly important in assisted reproductive technology (ART) and in patients with luteal phase deficiency.
Approved indications
- Luteal phase support in assisted reproductive technology (ART)
- Pregnancy maintenance in women with progesterone deficiency
Common side effects
- Vaginal irritation or discharge
- Headache
- Breast tenderness
- Abdominal discomfort
Key clinical trials
- First in Human Safety and Ease of Use Assessment of 400mg Progesterone Callavid in Women With Luteal Phase Insufficiency (PHASE1)
- Efficacy and Safety of Gushen Antai Pill on Ongoing Pregnancy Rate in Women With Normal Ovarian Reserve Undergoing IVF-ET (PHASE4)
- Postplacental Copper Intrauterine Device Versus Postpartum Progesterone-only Pills on Uterine Niche Formation (NA)
- Luteal Phase Support in IUI MOH Treatment Luteal Phase Support in IUI MOH Treatment (PHASE4)
- Cerclage With Progesterone Versus Progesterone Only in Singleton Pregnancies (NA)
- Estrogen Administration for the Treatment of NASH in Postmenopausal Women (PHASE3)
- A Study on the Correlation of Drug Metabolism and Human Body Composition Based on the Bioequivalence Trial of Progesterone Sustained-release Vaginal Gel
- Comparison of Two Protocols in Frozen Embryo Transfer (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Progesterone Vaginal Product CI brief — competitive landscape report
- Progesterone Vaginal Product updates RSS · CI watch RSS
- UMC Utrecht portfolio CI